CA2466499A1 - Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis - Google Patents

Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis Download PDF

Info

Publication number
CA2466499A1
CA2466499A1 CA002466499A CA2466499A CA2466499A1 CA 2466499 A1 CA2466499 A1 CA 2466499A1 CA 002466499 A CA002466499 A CA 002466499A CA 2466499 A CA2466499 A CA 2466499A CA 2466499 A1 CA2466499 A1 CA 2466499A1
Authority
CA
Canada
Prior art keywords
composition
chondroitin sulfate
weight
concentration
sodium hyaluronate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002466499A
Other languages
French (fr)
Other versions
CA2466499C (en
Inventor
Ochoa Elias Humberto Hermida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33297421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2466499(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2466499A1 publication Critical patent/CA2466499A1/en
Application granted granted Critical
Publication of CA2466499C publication Critical patent/CA2466499C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Abstract

This invention is related to the use of the composition formed by sodium hyaluronate and sodium chondroitin sulfate for the treatment of chondral lesions in osteoarthritis, and to the use of such composition in the manufacture of a product for such treatment.

Claims (20)

1. A therapeutic method for the treatment of a joint exhibiting degeneration of articular cartilage comprising the intraarticular administration to said joint of a viscous composition comprising a therapeutically effective amount of a mixture of chondroitin sulfate and hyaluronic acid or pharmaceutically acceptable salts thereof.
2. The method of claim 1, wherein the joint is in a human patient and the degeneration of the cartilage is caused by chondromalacia or osteoarthritis of grade I or grade II.
3. The method of either claim 1 or claim 2, wherein the composition comprises a mixture of chondroitin sulfate at a concentration of 0.1 to 50% by weight and sodium hyaluronate at a concentration of 0.1 to 50% by weight.
4. The method of claim 3, wherein the chondroitin sulfate concentration is from 0.1 to 5.3% by weight and the sodium hyaluronate concentration is from 0.1 to 4.2% by weight of the composition.
5. The method of claim 9, wherein the composition is a sterile, non-pyrogenic, viscoelastic solution comprising a mixture of chondroitin sulfate and sodium hyaluronate in a ratio of about 4 parts by weight chondroitin sulfate to about 3 parts by weight sodium hyaluronate.
6. The method of claim 5, wherein the concentration cf chondroitin sulfate is about 40 mg/ml and the concentration of, sodium hyaluronate is about 30 mg/ml.
7. The method of claim 6, wherein the chondroitin sulfate has a molecular weight of 20,000 to 50,000 daltons, the sodium hyaluronate has a molecular weight. of 5 00,000 to 1,000,000 daltons, and the composition has a. viscosity of 20,000 to 60,000 cps.
8. The method of claim 1, wherein doses of between 0.5 and 1.5 cubic centimeters of the viscoelastic composition are periodically administered to the affected joint.
9. The method of claim 8, wherein 2 to 6 doses of the viscoelastic composition are administered over 1 to 3 months.
10. The method of claim 9, wherein 2 to 4 doses of the viscoelastic composition are administered at 10 to 20 day intervals.
11. The method of claim 10, wherein 3 doses of the viscoelastic composition are administered at 15 day intervals.
12. The therapeutic method according to claim 8, wherein the joint is a human joint selected from the group formed by the following joints: i) knees, shoulders and sacroiliac; ii) coxofemoral, ankles and elbows; and iii) interphalangeal. and wrists.
13. The therapeutic method according to claim 12, wherein each dose of the viscoelastic composition is 1.5 cubic centimeters of the composition for the knee, shoulder or sacroiliac joints.
14. The therapeutic method according to claim 8, wherein each dose of the viscoelastic composition is 0.75 cubic centimeters of the composition for the coxofemoral, ankle or elbow joints.
15. The therapeutic method according to claim 8, wherein each dose of the viscoelastic composition is 0,5 cubic centimeters of the composition for the interphalangeal or wrist joints.
16. The use of stable, viscous, buffered aqueous solution which comprises a mixture of chondroitin sulfate at a concentration of about 0.1 to 50% by weight and sodium hyaluronate at a concentration of about 0.1 to 50% by weight in the manufacture of a product for the intraarticular treatment of chondromalacia and/or osteoarthritis.
17. The use according to claim 16, wherein said. solution is maintained at a pH of about 7.0 to 8Ø
18. The use according to claim 16 or claim 17, wherein the solution has an osmolarity of from about 300 to about 350 mOsmo1/kg.
19. A method of repairing or regenerating cartilage in a mammalian joint characterized by cartilage disease or trauma, comprising the intraarticular instillation of a mixture of chondroitin sulfate and hyaluronic acid or pharmaceutically acceptable salts thereof.
20. Use of a mixture of chondroitin sulfate and hyaluronic acid or pharmaceutically acceptable salts thereof in the manufacture of a product for intraarticular administration to repair or regenerate cartilage in a mammalian joint characterized by cartilage disease or trauma.
CA2466499A 2001-11-13 2002-11-13 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis Expired - Fee Related CA2466499C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
MXPA/A/2001/011542 2001-11-13
MXPA01011542A MXPA01011542A (en) 2001-11-13 2001-11-13 Regeneration of articular cartilage damaged by osteoarthritis i and ii, by means of intra-articular application of sodium hyaluronate and chondroitin sulphate in a gel carrier.
US10/082,743 US6906044B2 (en) 2001-11-13 2002-02-22 Regeneration of articular cartilage damaged by grade I and II osteoarthritis by means of the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate in a gel vehicle
US10/082,743 2002-02-22
PCT/EP2002/012703 WO2003041724A1 (en) 2001-11-13 2002-11-13 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis

Publications (2)

Publication Number Publication Date
CA2466499A1 true CA2466499A1 (en) 2003-05-22
CA2466499C CA2466499C (en) 2011-10-18

Family

ID=33297421

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2466499A Expired - Fee Related CA2466499C (en) 2001-11-13 2002-11-13 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis

Country Status (16)

Country Link
US (3) US6906044B2 (en)
EP (1) EP1443945B1 (en)
JP (2) JP4741183B2 (en)
KR (1) KR100989109B1 (en)
CN (1) CN1585645A (en)
AT (1) ATE411807T1 (en)
AU (1) AU2002363589B2 (en)
BR (1) BR0214032A (en)
CA (1) CA2466499C (en)
DE (1) DE60229545D1 (en)
DK (1) DK1443945T3 (en)
ES (1) ES2312648T3 (en)
HK (1) HK1064043A1 (en)
MX (2) MXPA01011542A (en)
WO (1) WO2003041724A1 (en)
ZA (1) ZA200402717B (en)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
EP1586329A1 (en) * 2000-02-08 2005-10-19 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
US20040118414A1 (en) 2002-12-20 2004-06-24 Shah Mandar V Surface modified viscoelastics for ocular surgery
US20040101561A1 (en) * 2002-11-13 2004-05-27 Jafari Masoud R. Combinations of viscoelastics for use during surgery
US7363928B2 (en) 2001-12-21 2008-04-29 Alcon, Inc. Dilution resistant viscoelastic compositions
US7820194B2 (en) * 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
KR20050094817A (en) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. Improved pharmaceutical botulinum toxin compositions
JP2007507516A (en) * 2003-10-01 2007-03-29 オプティマー・ファーマスーティカルズ・インコーポレイテッド Treatment of mammalian disorders by amino sugar administration and use of amino sugar
SI1677806T1 (en) * 2003-10-09 2009-06-30 Robert John Petrella Methods for treating acute and overuse sprain and strain using hyaluronic acid
DE102004019241A1 (en) * 2004-04-16 2005-11-03 Cellmed Ag Injectable cross-linked and uncrosslinked alginates and their use in medicine and aesthetic surgery
US20060003964A1 (en) * 2004-06-30 2006-01-05 Shah Mandar V Dilution resistant viscoelastic compositions
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
DE102004055729A1 (en) * 2004-11-18 2006-05-24 Cellmed Ag Production of two or more layered microcapsules
WO2006058109A1 (en) * 2004-11-23 2006-06-01 Alcon, Inc. Triple natural polymer viscoelastic composition
SI1835923T1 (en) * 2004-12-30 2014-01-31 Genzyme Coroporation Regimens for intra-articular viscosupplementation
WO2007008206A1 (en) * 2005-07-11 2007-01-18 Alcon, Inc. Dilution resistant viscoelastic compositions
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
JP4875865B2 (en) * 2005-08-17 2012-02-15 株式会社日本バリアフリー NTx value reducing agent for prevention and treatment of osteoarthritis
ES2281265B1 (en) * 2005-11-24 2008-08-16 Bioiberica, S.A. COMPOSITIONS FOR THE TREATMENT OF ARTROSIS.
ITMI20061030A1 (en) 2006-05-26 2007-11-27 Altergon Sa NEW COMPOSITION INCLUDING GLYCOSAMINOGLICANS WITH CONTROLLED VISCOSITY AND USE OF SUCH COMPOSITION IN THE THERAPY OF CHRONIC CYSTITIS
TW200743492A (en) * 2006-05-29 2007-12-01 Ching-Chuan Jiang Hyaluronic acid used for purpose of anti-oxidation and proliferation on cartilage cells
ITPD20060219A1 (en) 2006-05-31 2007-12-01 Fidia Farmaceutici PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID SULFATED IN THE TREATMENT OF OSTEOARTHROSIS
CN100417415C (en) * 2006-06-28 2008-09-10 文彦春 Soakage of medication for treating arthritis
US20080069855A1 (en) * 2006-08-21 2008-03-20 Bonutti Peter M Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss
ES2304886B1 (en) * 2007-04-13 2009-11-11 Bioiberica, S.A. "COMPOSITIONS TO NUTRIR THE ARTICULATIONS".
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
CA3115223A1 (en) * 2007-07-10 2011-01-13 Implantica Patent Ltd. Hip joint device and method
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2082755A1 (en) * 2008-01-16 2009-07-29 CellMed AG Monolithic alginate implants networked in situ
US8828354B2 (en) 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
CN102065929B (en) 2008-06-26 2013-11-06 凯希特许有限公司 System for stimulation of cartilage formation using reduced pressure treatment
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US9161903B2 (en) * 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
KR20110107357A (en) * 2008-12-30 2011-09-30 케이씨아이 라이센싱 인코포레이티드 Reduced pressure augmentation of microfracture procedures for cartilage repair
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
IT1393945B1 (en) 2009-04-21 2012-05-17 Fidia Farmaceutici COMPOSITIONS INCLUDING HYALURONIC ACID, HYALURONIC ACID, SULFATE, CALCIUM AND VITAMIN D3 IN THE TREATMENT OF OSTEOARTICULAR AND MUSCULOSCHELETAL DISEASES
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
CN101690728B (en) * 2009-09-23 2011-09-21 沈阳亿灵医药科技有限公司 Composition for treating osteoarthritis
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US8758791B2 (en) 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US8475824B2 (en) 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
WO2012075451A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
WO2012075447A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
US20120142628A1 (en) * 2010-12-07 2012-06-07 Allergan, Inc. Methods for treating crepitus
US8398611B2 (en) * 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9186377B2 (en) 2011-06-03 2015-11-17 Maguire Abbey, Llc Method, composition, and articles for improving joint lubrication
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
PL2596796T3 (en) 2011-11-24 2014-04-30 Quimera Ingenieria Biomedica S L Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures
ITPD20120098A1 (en) * 2012-03-30 2013-10-01 Fidia Farmaceutici "NEW PHARAMACEUTICAL FORMULATIONS CONTAINING CONDROITIN SULFATE AND DERIVATIVES OF HYALURONIC ACID"
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
US9180223B2 (en) 2012-05-10 2015-11-10 The Trustees Of The Stevens Institute Of Technology Biphasic osteochondral scaffold for reconstruction of articular cartilage
FR2991876B1 (en) 2012-06-13 2014-11-21 Vivacy Lab COMPOSITION, IN AQUEOUS MEDIUM, COMPRISING AT LEAST ONE HYALURONIC ACID AND AT LEAST ONE WATER-SOLUBLE SALT OF SUCROSE OCTASULFATE
PT2900247T (en) * 2012-09-26 2018-03-28 Bone Therapeutics Sa Compositions comprising solvent/detergent-treated plasma and hyaluronic acid for use in the treatment of muskuloskeletal disorders
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
ITMI20132116A1 (en) 2013-12-18 2015-06-19 Apharm Srl ASSOCIATION OF GLYCOSAMINOGLICANS AND CYCLODESTRINES
EP3760186A1 (en) * 2014-04-30 2021-01-06 Allergan, Inc. Formulations of biologics for intravesical instillation
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
EP3000489B1 (en) 2014-09-24 2017-04-05 Sofradim Production Method for preparing an anti-adhesion barrier film
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
CN105982912A (en) * 2015-03-02 2016-10-05 黄绣川 Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate
EP3111941A1 (en) 2015-06-30 2017-01-04 Süleyman Patir Compositions comprising chondroitin sulfate for prophylaxis or treatment of damaged articular cartilage
KR101637883B1 (en) * 2015-09-30 2016-07-21 선바이오(주) Polyethylene glycol hydrogel injection
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
KR101895950B1 (en) * 2015-12-18 2018-09-06 (주)한국비엠아이 Composition for treating osteoarthritis comprising hydrophilized sulfasalazine and hyaluronic acid and method for preparing the same
USD802755S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
JP7217700B2 (en) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド Stabilized non-protein Clostridial toxin composition
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
KR102364483B1 (en) * 2019-07-04 2022-02-21 백우인 Nutrition material for pets with natural materials
CN111955722A (en) * 2020-08-05 2020-11-20 山东明仁福瑞达制药股份有限公司 Medical nutrition meal composition beneficial to medicine absorption and recovery and used for rehabilitation of osteopathic patients and medical nutrition meal
CN112245395A (en) * 2020-11-20 2021-01-22 佳木斯大学 Medical cartilage repairing agent and preparation method thereof
US11318187B1 (en) * 2021-09-02 2022-05-03 Bjorn Eek Treatment of internal disc disruption and connective tissue injuries

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486416A (en) 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
US4971955A (en) 1981-03-02 1990-11-20 Soll David B Protection of human and animal cells during surgical trauma
US5409904A (en) 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US5340579A (en) * 1984-11-20 1994-08-23 Farmaka S.R.L. Method of treating dermatological conditions
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5099013A (en) 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION
US6051560A (en) * 1986-06-26 2000-04-18 Nestle S.A. Chrondroitin sulfate/sodium hyaluronate composition
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
IT1270095B (en) * 1994-09-28 1997-04-28 Ibsa Inst Biochimique Sa THERAPEUTIC COMPOSITIONS OF CHONDROITIN SULPHATE IN THE FORM OF ORAL ADMINISTRABLE GEL
IT1291291B1 (en) 1997-04-30 1999-01-07 Chemedica Sa USE OF HYALURONIC ACID AND RELATIVE SALTS FOR THE PREPARATION OF A WATER SOLUTION USEFUL AS INTRA-ARTICULAR WASHING LIQUID
US5929050A (en) 1998-02-27 1999-07-27 Petito; George D. Chondroitin sulfate composition and method for wound treatment
JP2000072678A (en) * 1998-06-15 2000-03-07 Takeda Chem Ind Ltd Chondropathy preventive and therapeutic agent
WO2000044367A2 (en) 1999-02-01 2000-08-03 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
ES2374157T3 (en) * 2002-10-16 2012-02-14 Arthrodynamic Technologies, Animal Health Division, Inc. TREATMENT FOR TRAUMATIC SYNOVITIS AND DAMAGED ARTICULAR CARTRIDGE.

Also Published As

Publication number Publication date
ATE411807T1 (en) 2008-11-15
MXPA01011542A (en) 2003-05-22
DK1443945T3 (en) 2009-01-12
WO2003041724A1 (en) 2003-05-22
EP1443945B1 (en) 2008-10-22
US6906044B2 (en) 2005-06-14
KR100989109B1 (en) 2010-10-25
CN1585645A (en) 2005-02-23
DE60229545D1 (en) 2008-12-04
ES2312648T3 (en) 2009-03-01
BR0214032A (en) 2004-10-13
US20040214793A1 (en) 2004-10-28
ZA200402717B (en) 2005-02-23
MXPA04004452A (en) 2004-08-11
CA2466499C (en) 2011-10-18
HK1064043A1 (en) 2005-01-21
EP1443945A1 (en) 2004-08-11
JP2005515181A (en) 2005-05-26
US6949525B2 (en) 2005-09-27
KR20050044415A (en) 2005-05-12
AU2002363589B2 (en) 2007-11-29
US20040082540A1 (en) 2004-04-29
US20050244358A1 (en) 2005-11-03
JP4741183B2 (en) 2011-08-03
JP2011105741A (en) 2011-06-02

Similar Documents

Publication Publication Date Title
CA2466499A1 (en) Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
Iwata Pharmacologic and clinical aspects of intraarticular injection of hyaluronate
JP5815206B2 (en) Treatment of cartilage disorders using FGF-18
JP4511031B2 (en) Intra-articular injection composition and injectable aqueous composition preparation method
AU2002363589A1 (en) Use of a mixture of sodium hyaluronate and chondroitin sulfate for a treatment of osteoarthritis
US20070054878A1 (en) Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis
TWI565470B (en) Use of hyaluronic acid and pharmacetical composition for inhibiting pain
ES2392883T3 (en) Treatment of cartilage disorders with FGF-18
TWI383796B (en) Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
US20080139500A1 (en) Use of composite monomer or monomers, catalyst, sodium hyaluronate or hyaluronic acid, glucosamide sulfate, chondroiten sulfate or chlorides, for the treatment of osteoarthritis by intraarticular application to a hip or knee joint
US20220280555A1 (en) Composition Comprising Hyaluronic Acid and Pluronic for Preventing or Treating Articular and Cartilage Injury
CN110050003A (en) Lubricate block copolymer and its purposes as biomimetic type boundary lubrication agent
US9040575B2 (en) Combination for the treatment of osteoarthritis
WO2024080954A1 (en) Intra-articular gel for tissue and cartilage regeneration
CN107840897A (en) It is a kind of to be used to treat hyaluronic acid magnesium salts of osteoarthritis and its preparation method and application
EP4084801A1 (en) A novel viscoelastic formulation for osteoarthritis treatment and a production method thereof
Brief et al. Perspectives on Modern Orthopaedics Use of Gluscosamine and Chondroitin Sulfate in the Management of Osteoarthritis
Rovenský Jozef Rovenský, Helena Tauchmannová, Mária Stančíková, Jana Sedláková, and Mária Krátka
UA78163C2 (en) Glucosamine-containing drug for treating diseases of joints

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201113